“We have secured 20,000 doses experimental antiviral drug developed by the pharmaceutical company Merck “to address COVID-19,” South Korean Prime Minister Kim Jong-un said on Wednesday (6/10). At the same time Other Asian countries are showing great interest in the coronavirus pill, while Australia has already started buying it.
The pharmaceutical company Merck announced a supply and market agreement with Singapore while Thailand, Taiwan and Malaysia have said they are in talks to buy it.
New Merck Coronavirus Pill Reduces Hospitalization and Deaths by 50%
Molnupiravir, which is preparing to become the first oral antiviral drug against COVID-19, may halve the chances of death or hospitalization for those most at risk of catching a severe form of COVID-19. Merck is seeking approval from the Food and Drug Administration (FDA) for its pill.
Treatment involves giving patients four pills twice a day for five days.
“We have already secured a sufficient budget for the treatment of some 40,000 people and we have signed a 20,000-dose pre-purchase agreement,” Kim told a COVID-19 response committee meeting today.
South Korea is also seeking to buy other antiviral drugs, the Athenian News Agency reported.
“We are planning a gradual pricing of the preparation,” the company explains
Merck has announced that it is planning a gradual pricing of its formulation based on income criteria by country. The US government has a $ 1.7 billion contract for $ 700 per share.
The Korean Agency for Disease Control and Prevention (KDCA), for its part, said it was also in talks with Pfizer and Swiss Roche, who have also been involved in the fight to develop a antiviral pill against COVID-19.
The South Korean government has earmarked 36.2 billion won in the budget for antiviral pills to treat COVID-19.
South Korea has a fairly low mortality rate -0.76% until yesterday Tuesday (5/10) – patients in critical condition.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
